Key Takeaways

A phase I trial indicated that a cancer vaccine that targets KRAS mutations prolonged survival in patients with pancreatic and colorectal cancers.

Patients with the strongest T-cell responses specific to KRAS mutations lived longer and remained recurrence free longer than those with weaker responses.

Previous results also showed that the vaccine was safe, with no dose-limiting toxicities.

An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive survival outcomes in patients with resected pancreatic and colorectal cancers, according to final results from the phase I AMPLIFY-201 trial.

Among 25 patients with minimal residual disease (MRD) after standard locoregional treatment, median relapse-free survival

See Full Page